Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib plus Atezolizumab in Solid Tumors (COTEST)
NCT03264066Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of cobimetinib in squamous cell carcinoma of the head and neck (HNSCC), urothelial carcinoma (UC) and renal cell carcinoma (RCC) (7 arms), sponsored by Roche. Primary endpoint: Objective Response Rate up to 31 months. Started Nov 2017; status: completed.
02
Drugs
cobimetinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)urothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03264066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264066.